The Technical Analyst
Avita Therapeutics Inc [RCEL]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Avita Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.59% $8.64
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 222.11 mill |
| EPS: | -1.400 |
| P/E: | -6.17 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 25.71 mill |
| Avg Daily Volume: | 0.224 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.17 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -6.17 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 7.86 - 9.42 ( +/- 9.06%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | O'toole David D | Buy | 250 | Common Stock |
| 2024-02-28 | O'toole David D | Buy | 1 000 | Common Stock |
| 2024-01-03 | Shiroma Donna | Buy | 100 000 | Stock Options (Right to Buy) |
| 2023-11-30 | Shiroma Donna | Buy | 1 469 | Common Stock |
| 2024-01-03 | O'toole David D | Buy | 125 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 72.36 |
| Last 97 transactions |
| Buy: 1 597 984 | Sell: 352 272 |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.64
Forecast 2: 16:00 - $8.64
Forecast 3: 16:00 - $8.64
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.64 (-2.59% ) |
| Volume | 0.368 mill |
| Avg. Vol. | 0.224 mill |
| % of Avg. Vol | 164.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RCEL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $17.50 | N/A | Active |
|---|
RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 17:05:00 - Press Release
Avita Medical To Announce First Quarter 2024 Financial Results
Avita medical will report first quarter 2024 financial results after the close on may 13, 2024, and host a webcast that day at 1:30 p.m. pacific time.
2024-04-10 17:11:00 - Press Release
Avita Medical Updates Expected First Quarter 2024 Revenue
Avita medical updates expected q1 2024 commercial revenue; reaffirms expectations for full-year 2024 revenue at lower end of previously provided guidance.
2024-02-29 16:02:00 - Press Release
Avita Medical Submits Response To Fda, Resuming Review Clock For Recell Go Pma Supplement
Avita medical submitted its response to fda for additional information in connection to recell go pma supplement. submission resumes substantive review.
2024-02-29 09:00:00 - Press Release
Avita Medical To Present At Td Cowen 44th Annual Health Care Conference
Valencia, calif., feb. 29, 2024 (globe newswire) -- avita medical, inc. (nasdaq: rcel, asx: avh), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that david o'toole, chief financial officer, will present at td cowen's 44th annual health care conference on tuesday, march 5, 2024, at 9:50 a.m.
2024-02-23 09:01:00 - Press Release
Avita Medical To Host Investor Webinar Briefing
Valencia, calif., feb. 23, 2024 (globe newswire) -- avita medical, inc. (nasdaq: rcel, asx: avh), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by jim corbett, chief executive officer, and david o'toole, chief financial officer, on february 27, 2024, at 2:00 p.m.
Latest News
2024-04-15 17:05:00 - GlobeNewsWire
AVITA Medical to Announce First Quarter 2024 Financial Results
AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time.
2024-02-29 09:00:00 - GlobeNewsWire
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will present at TD Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m.
2024-02-22 23:03:08 - Seeking Alpha
AVITA Medical, Inc. (RCEL) Q4 2023 Earnings Call Transcript
2024-02-01 16:10:00 - GlobeNewsWire
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024.
2024-01-04 09:00:00 - GlobeNewsWire
AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P.
2023-12-19 20:38:32 - Seeking Alpha
AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum
AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the supplement of its RECELL System for full-thickness skin defects. AVITA's expanded FDA label approval has significantly increased its addressable market, with an opportunity in excess of $2.7 billion in the US alone.
2023-11-22 09:46:08 - Zacks Investment Research
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
2023-11-21 16:15:00 - GlobeNewsWire
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time.
2023-11-09 20:39:04 - Seeking Alpha
AVITA Medical, Inc. (RCEL) Q3 2023 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Brooks O'Neil - Lake Street Capital Markets John Hester - Bell Potter Ross Osborne - Cantor Fitzgerald Madeline Williams - Wilsons Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Third Quarter 2023 Earnings Call.
2023-10-19 16:05:00 - GlobeNewsWire
AVITA Medical to Announce Third Quarter 2023 Financial Results
VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 10, 2023, at 7:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.